As for Novik, I really want to give him more credit, but:
1) his (And prolor's) inexperience is evident during the phase II trial. Right now it is taking about twice as long as they said it would when they started. (it was supposed to end in the first quarter).
2) I get the feeling he is not being completely honest with us. For example, he makes it sound like Merck might get approval for Elonva in the US soon, when in fact, they are now conducting a phase 3 in the us which would not end before october 2012, meaning they will not get approval before the end of 2013, almost 3 years from now.
thanx for the warm welcome. I guess that being a president of Prolor, Novik has more wall street track record than you imagine. Do you really think he can say what he knows? You can never time clinical human trials to be exactly when you plan. Ask any phisician.
That was an interesting concept until a few weeks ago. My guess is now with the recent surge in covering, the short outstanding is relatively low and will be meaningless come announcement time. More importantly with the drastic drop in price, I will be very surprised if we see double digits anytime soon. I hope we do but that is a long way to go from here, Phase II or not.